Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Mackinnon

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Blood|December 28, 2017
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiencyThomas A Fox, Ronjon Chakraverty, Siobhan Burns, et al.
Haematologica|December 3, 2009
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemiaCharles Craddock, Sandeep Nagra, Andrew Peniket, et al.
British Journal of Haematology|November 19, 2015
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocolsRachael Hough, Robert Danby, Nigel Russell, et al.
Genome Medicine|December 17, 2015
A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantationDirk S Paul, Allison Jones, Rob S Sellar, et al.
Blood|July 1, 2010
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitutionRonjon Chakraverty, Guillermo Orti, Michael Roughton, et al.
Blood|January 25, 2002
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenRonjon Chakraverty, Karl Peggs, Rajesh Chopra, et al.
British Journal of Haematology|September 15, 2007
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs, Anna Sureda, Wendi Qian, et al.
Blood|February 26, 2005
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMTCharles Crawley, Marc Lalancette, Richard Szydlo, et al.
Blood|October 18, 2002
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disordersJosé A Pérez-Simón, Panagiotis D Kottaridis, Rodrigo Martino, et al.
British Journal of Haematology|August 10, 2019
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemiaRob S Sellar, Varun Mehra, Thomas A Fox, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Blood|December 28, 2017
Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiencyThomas A Fox, Ronjon Chakraverty, Siobhan Burns, et al.
Haematologica|December 3, 2009
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemiaCharles Craddock, Sandeep Nagra, Andrew Peniket, et al.
British Journal of Haematology|November 19, 2015
Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocolsRachael Hough, Robert Danby, Nigel Russell, et al.
Genome Medicine|December 17, 2015
A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantationDirk S Paul, Allison Jones, Rob S Sellar, et al.
Blood|July 1, 2010
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitutionRonjon Chakraverty, Guillermo Orti, Michael Roughton, et al.
Blood|January 25, 2002
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimenRonjon Chakraverty, Karl Peggs, Rajesh Chopra, et al.
British Journal of Haematology|September 15, 2007
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomesKarl S Peggs, Anna Sureda, Wendi Qian, et al.
Blood|February 26, 2005
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMTCharles Crawley, Marc Lalancette, Richard Szydlo, et al.
Blood|October 18, 2002
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disordersJosé A Pérez-Simón, Panagiotis D Kottaridis, Rodrigo Martino, et al.
British Journal of Haematology|August 10, 2019
Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemiaRob S Sellar, Varun Mehra, Thomas A Fox, et al.
Pageof 11